MEDIFAST INC

As of June 30, 2026, Medifast, Inc. carries a market capitalization of 120.42M, placing it among publicly traded companies globally. Its enterprise value stands at -21.78M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Medifast, Inc.'s next confirmed earnings release is scheduled for October 26, 2026.

As of June 30, 2026, Medifast, Inc. has 11.18M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.37, and the price-to-book ratio stands at 0.61.

As of June 30, 2026, Medifast, Inc. maintains a current ratio of 4.86, meaning it holds 4.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Medifast, Inc. posted a negative return on equity (ROE) of -12.42, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -9.67, reflecting losses generated across the asset base. The company generates approximately 771,126.52 in revenue per employee across its workforce of 411.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.79 indicates how many times Medifast, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Medifast, Inc. recorded 11.63M in income tax expense. The company reported a pretax loss of -13.97M and -25.60M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Medifast, Inc.'s stock has declined approximately 6.25% over the past 52 weeks. The 50-day moving average sits at 11.97, while the 200-day moving average is 11.32.

Over the twelve months ended June 30, 2026, Medifast, Inc. generated 316.93M in revenue and converted that into -25.60M in net income, yielding earnings per share of -2.32. EBITDA reached -5.66M, while operating income came in at -19.51M.

As of June 30, 2026, Medifast, Inc. holds 169.82M in cash and equivalents against 27.62M in total debt, resulting in a net debt position of -71.91M. Total book value stands at 196.38M, with working capital of 160.47M providing operational flexibility.

Medifast, Inc. produced 8.79M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -4.78M in capital expenditures, free cash flow totaled 4.01M - equivalent to 0.36 per share.

Over the twelve months ended June 30, 2026, Medifast, Inc. posted a gross margin of 69.24, reflecting its pricing power and cost economics. The operating margin of -6.15 and net profit margin of -8.08 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Medifast, Inc. paid dividends of 0.02 per share. The dividend payout ratio of -0.66 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 3.38, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.82, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Medifast, Inc. shareholders.

As of June 30, 2026, Medifast, Inc. has an Altman Z-Score of 3.66, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.